Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.27% to 6,051.97 and Dow Jones Industrial Average falling 0.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price target for GILD stock.

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks,